AZ3391
AZ3391 is a potent inhibitor of PARP. AZ3391 is a quinoxaline derivative. PARP family of enzymes play an important role in a number of cellular processes, such as replication, recombination, chromatin remodeling, and DNA damage repair. AZ3391 has the potential for the research of diseases and conditions occurring in tissues in the central nervous system, such as the brain and spinal cord (extracted from patent WO2021260092A1, compound 23) [1].
Product Specifications
CAS Number
2756333-42-1
UNSPSC
12352005
Target
PARP
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer; Neurological Disease
Assay Protocol
https://www.medchemexpress.com/az3391.html
Purity
98.03
Solubility
DMSO : 16.67 mg/mL (ultrasonic)
Smiles
O=C(C1=NC(C)=C(N2CCN(CC3=C(F)C4=C(N=C(CC)C(N4)=O)C=C3)CC2)C=C1)NC
Molecular Formula
C23H27FN6O2
Molecular Weight
438.50
References & Citations
[1]Martin John Packer, et al. Quinoxaline derivatives as anti-cancer drugs. Patent WO2021260092A1.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Available Sizes
Frequently Asked Questions
Explore Other Products
Browse additional items from our catalog
